HLA-C and colorectal carcinoma: In T-cell receptor therapy (TCR), T cells are equipped with a new T-cell receptor that targets a specific TAA presented by an MHC molecule.20 For patients living with CRC, carcinoembryonic antigen is a common target antigen because it is frequently upregulated in this cancer.21 MHC-mediated killing such as this requires autologous T cells (from the patient) or MHC-matched T cells from donors.